华海药业股票讨论区

Zhejiang Huahai Pharmaceutical's share price drop doesn't align with its EPS growth and revenue increase, hinting at other influencing factors. Last year's performance suggests unresolved issues, and long-term share price weakness could be a negative sign or a potential turnaround for contrarian investors.